QQQ   273.06 (+0.44%)
TSLA   1,614.00 (+3.81%)
BA   174.00 (-0.82%)
QQQ   273.06 (+0.44%)
TSLA   1,614.00 (+3.81%)
BA   174.00 (-0.82%)
QQQ   273.06 (+0.44%)
TSLA   1,614.00 (+3.81%)
BA   174.00 (-0.82%)
QQQ   273.06 (+0.44%)
TSLA   1,614.00 (+3.81%)
BA   174.00 (-0.82%)
Log in

NASDAQ:XBITXBiotech Stock Price, Forecast & News

$16.44
+0.37 (+2.30 %)
(As of 08/13/2020 09:30 AM ET)
Add
Compare
Today's Range
$15.92
Now: $16.44
$17.55
50-Day Range
$13.97
MA: $15.02
$17.54
52-Week Range
$7.18
Now: $16.44
$26.40
Volume394,963 shs
Average Volume476,291 shs
Market Capitalization$474.33 million
P/E Ratio1.13
Dividend YieldN/A
Beta1.41
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Read More
XBiotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$18.20 per share

Profitability

Net Income$668.63 million

Miscellaneous

Employees56
Market Cap$474.33 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable
$16.44
+0.37 (+2.30 %)
(As of 08/13/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











XBiotech (NASDAQ:XBIT) Frequently Asked Questions

How has XBiotech's stock been impacted by COVID-19?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBIT shares have increased by 53.4% and is now trading at $16.44.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of XBiotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for XBiotech
.

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for XBiotech
.

What price target have analysts set for XBIT?

2 analysts have issued 12-month price objectives for XBiotech's stock. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's stock price to reach $23.00 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for XBiotech
.

Has XBiotech been receiving favorable news coverage?

Media coverage about XBIT stock has trended extremely negative on Thursday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. XBiotech earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
View the latest news about XBiotech
.

Are investors shorting XBiotech?

XBiotech saw a decrease in short interest in the month of February. As of February 15th, there was short interest totaling 3,510,000 shares, a decrease of 27.2% from the January 31st total of 4,820,000 shares. Based on an average daily trading volume, of 879,000 shares, the days-to-cover ratio is presently 4.0 days. Approximately 17.2% of the shares of the stock are sold short.
View XBiotech's Short Interest
.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Ocular Therapeutix (OCUL), Vaxart (VXRT) and SCYNEXIS (SCYX).

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.39%), Bank of New York Mellon Corp (0.22%), Alps Advisors Inc. (0.14%), Strs Ohio (0.12%), Goldman Sachs Group Inc. (0.11%) and Swiss National Bank (0.11%). Company insiders that own XBiotech stock include Fondation Rennes, Street Financial SA Bay, W Thorpe Mckenzie and W Thorpe Mckenzie.
View institutional ownership trends for XBiotech
.

Which institutional investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Alps Advisors Inc..
View insider buying and selling activity for XBiotech
.

Which institutional investors are buying XBiotech stock?

XBIT stock was acquired by a variety of institutional investors in the last quarter, including Swiss National Bank, WINTON GROUP Ltd, Bank of New York Mellon Corp, Strs Ohio, Russell Investments Group Ltd., Virtus ETF Advisers LLC, California Public Employees Retirement System, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie.
View insider buying and selling activity for XBiotech
.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $16.44.

How big of a company is XBiotech?

XBiotech has a market capitalization of $474.33 million. The biopharmaceutical company earns $668.63 million in net income (profit) each year or ($0.68) on an earnings per share basis. XBiotech employs 56 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.